ACR-368 (prexasertib)
Multiple high unmet need solid cancer types (ovarian, endometrial, head and neck squamous cell carcinoma)
Key Facts
About Acrivon Therapeutics
Acrivon Therapeutics is pioneering a proteomics-based approach to precision oncology with its AP3 platform, which directly measures disease-driving protein activity to overcome the limitations of genomic biomarkers. The company has built a pipeline focused on DNA Damage Response and cell cycle targets, led by the Phase 2 candidate ACR-368, and is developing internally discovered compounds including ACR-2316 (dual WEE1/PKMYT1 inhibitor) and ACR-6840 (CDK11 inhibitor). With operations in Boston and Scandinavia, Acrivon aims to transform cancer treatment by accurately matching therapies to patients most likely to respond, addressing high unmet needs in prevalent solid tumors.
View full company profile